Want Decades of Passive Income? 2 Stocks to Buy Right Now

Northrop Grumman and Lockheed Martin are presented as durable, dividend-paying defense stocks benefiting from sustained U.S. military spending amid geopolitical tensions. Northrop has increased its dividend for 21 consecutive years (1.7% yield, 10-year dividend CAGR 11.9%) and Lockheed for 22 years (2.3% yield, 10-year dividend CAGR 9.8%); both reportedly pay out roughly half of earnings. Flagship programs cited for long-term revenue visibility include Northrop's B-21 Raider (potentially >$200 billion lifetime) and Lockheed's F-35 program (estimated ~$2 trillion lifetime through 2088), while shares trade near their decade-average P/E and have outperformed the S&P 500. The piece is a positive, dividend-focused investment view rather than new corporate disclosure.

Analysis

Market structure: The immediate winners are large U.S. prime contractors (NOC, LMT), Tier-1 suppliers, and sustainment/MRO vendors because multi-decade programs (B-21 ~$200B lifetime; F-35 ~$2T lifetime) create sticky revenue and pricing power. Losers include discretionary commercial aerospace and non-U.S. competitors when U.S. procurement and foreign military sales (FMS) crowd the supply chain; input-cost inflation (titanium, specialty alloys, semiconductors) tightens margins unless fully pass-through. Cross-asset: sustained defense demand tends to widen fiscal deficits, pressuring long-duration Treasuries (term premium +/−), lift industrial metals, increase USD safe-haven bids on escalation, and raise implied vol for defense single-name options.

Risk assessment: Tail risks include abrupt Congressional austerity/sequestration, major program cost overruns or a catastrophic B-21/F-35 test failure, and export restrictions that cut FMS revenue; probability low but impact high. Time horizons matter: days–weeks = headline-driven volatility; months = contract awards and budget cycles (watch appropriations in next 3–9 months); years = program cash flows into 2050s–2088. Hidden dependencies: semiconductor/specialty metal suppliers, foreign government approvals, and DoD sustainment budgets drive aftermarket margins more than new-build timing. Catalysts: DoD milestone announcements, FY appropriations votes, major international F-35/FMS orders in the next 6–12 months.

trade implications: Core actionable overweight: LMT for yield and F-35 scale, NOC for program optionality (B-21). Tactical implementation: establish modest core long positions (2–4% portfolio combined), use covered-call overlays (3-month, ~5% OTM) to boost income, and size LEAP call exposure (9–18 month, 15–25% OTM) for asymmetric upside tied to contract wins. Pair and hedges: consider long LMT / short NOC 1:1 notional on expectation F-35 sustainment & international sales outpace B-21 near-term; use 3–6 month puts to cap downside to ~5–10% per position.

Key Decisions for Investors

• Establish a 2.5% portfolio weight in LMT today (or stagger 50/50 now and on a >8% pullback); target holding horizon 12–36 months to capture F-35 sustainment cash flow; hedge with a 3–6 month ATM put sized to limit downside to ~7–10% of notional or sell 3-month covered calls 4–6% OTM to boost yield.
• Establish a 1.5% portfolio weight in NOC with a staggered buy (50% now, 50% on >10% drop); hold 18–48 months to capture B-21 program optionality; if exposure >1.5%, buy 9–12 month puts (5–7% notional) to protect against budget or test-failure tail risk.
• Implement a tactical pair trade: long LMT / short NOC 1:1 notional sized at 1–2% net portfolio risk to express relative F-35 vs B-21 execution; unwind after 9–18 months or at the next material DoD milestone (first B-21 flight or major F-35 international order).
• Allocate 0.5–1.0% notional to long-dated LEAP calls on LMT (9–18 month, 15–25% OTM) as asymmetric upside exposure; cap total options premium to <=1% portfolio risk to avoid concentrated gamma exposure.
• Monitor three specific triggers in the next 90–270 days before scaling: (1) Congressional defense appropriations vote outcome (timing/magnitude of topline), (2) official B-21 test milestone or cost overrun disclosure, and (3) any new F-35 international sales announcements—add to positions on positive outcomes, trim on negative outcomes exceeding 10% price impact.